Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis.

ABSTRACT:

Background & aims

Progressive fibrosis has been identified as the major predictor of mortality in patients with non-alcoholic fatty liver disease (NAFLD). Several biomarkers are currently being evaluated for their ability to substitute the liver biopsy as the reference standard. Recent clinical studies in NAFLD/NASH patients support the utility of PRO-C3, a marker of type III collagen formation, as a marker for the degree of fibrosis, disease activity, and effect of treatment. Here we establish the healthy reference range, optimal sample handling conditions for both short- and long-term serum storage, and robustness for the PRO-C3 assay.

Methods

PRO-C3 was measured in 269 healthy volunteers and in 222 NAFLD patients. Robustness of the PRO-C3 assay was measured according to C

SUBMITTER: Erhardtsen E 

PROVIDER: S-EPMC8385245 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature